trial · primary record
MDSY-1240
Triple-Negative Breast Cancer (TNBC)
| Phase | Phase 1, Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 75 |
| Primary completion | 2029-09 |
| Primary endpoint | Part 1 (Dose Escalation): Number of Participants With Treatment-Emergent Adverse Events (TEAEs) |
| Registry ID | NCT07899632 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T02:32:46.754Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07899632
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.